Jayson Bedford
Stock Analyst at Raymond James
(3.99)
# 636
Out of 4,761 analysts
303
Total ratings
58.39%
Success rate
8.67%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Reiterates: Outperform | $294 → $328 | $282.80 | +15.98% | 26 | Feb 21, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $126 → $119 | $104.83 | +13.52% | 7 | Feb 7, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $119 → $122 | $104.49 | +16.76% | 24 | Feb 6, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $560 → $688 | $591.79 | +16.26% | 8 | Jan 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $170 → $165 | $162.30 | +1.66% | 21 | Jan 23, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $105 → $110 | $103.16 | +6.63% | 26 | Dec 31, 2024 | |
| MASI Masimo | Maintains: Outperform | $170 → $194 | $169.96 | +14.14% | 6 | Dec 27, 2024 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $88.78 | +11.51% | 30 | Oct 25, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $122 → $129 | $134.92 | -4.39% | 27 | Oct 14, 2024 | |
| ICUI ICU Medical | Maintains: Outperform | $158 → $190 | $157.26 | +20.82% | 19 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $227.43 | +18.72% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $18.00 | -27.78% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $10.33 | -3.19% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $175.64 | +54.29% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.75 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $31.00 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $73.30 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $33.82 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $89.94 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.96 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $64.49 | +33.35% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.08 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.13 | - | 3 | Jan 2, 2018 |
Insulet
Feb 21, 2025
Reiterates: Outperform
Price Target: $294 → $328
Current: $282.80
Upside: +15.98%
Zimmer Biomet Holdings
Feb 7, 2025
Maintains: Outperform
Price Target: $126 → $119
Current: $104.83
Upside: +13.52%
Boston Scientific
Feb 6, 2025
Maintains: Strong Buy
Price Target: $119 → $122
Current: $104.49
Upside: +16.76%
Intuitive Surgical
Jan 24, 2025
Maintains: Outperform
Price Target: $560 → $688
Current: $591.79
Upside: +16.26%
Johnson & Johnson
Jan 23, 2025
Maintains: Outperform
Price Target: $170 → $165
Current: $162.30
Upside: +1.66%
Merit Medical Systems
Dec 31, 2024
Maintains: Outperform
Price Target: $105 → $110
Current: $103.16
Upside: +6.63%
Masimo
Dec 27, 2024
Maintains: Outperform
Price Target: $170 → $194
Current: $169.96
Upside: +14.14%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $88.78
Upside: +11.51%
Abbott Laboratories
Oct 14, 2024
Maintains: Outperform
Price Target: $122 → $129
Current: $134.92
Upside: -4.39%
ICU Medical
Sep 12, 2024
Maintains: Outperform
Price Target: $158 → $190
Current: $157.26
Upside: +20.82%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $227.43
Upside: +18.72%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $18.00
Upside: -27.78%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $10.33
Upside: -3.19%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $175.64
Upside: +54.29%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.75
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $31.00
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $73.30
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $33.82
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $89.94
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.96
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $64.49
Upside: +33.35%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.08
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $21.13
Upside: -